Jelonek Katarzyna, Jaworska Joanna, Musiał-Kulik Monika, Stojko Mateusz, Włodarczyk Jakub, Sobota Michał, Pastusiak Małgorzata, Smola-Dmochowska Anna, Szewczenko Janusz, Goldsztajn Karolina, Dobrzyński Piotr, Kasperczyk Janusz
Centre of Polymer and Carbon Materials, Polish Academy of Sciences, Curie-Sklodowska 34 St., 41-819 Zabrze, Poland.
Department of Biomaterials and Medical Devices Engineering, Faculty of Biomedical Engineering, Silesian University of Technology, 41-800 Zabrze, Poland.
Int J Mol Sci. 2025 Aug 7;26(15):7649. doi: 10.3390/ijms26157649.
Restenosis is the main cause of failure after stent implantation during angioplasty. The localized, sustained delivery of an antirestenotic drug may reduce smooth muscle cell (SMCs) proliferation and thereby limit neointimal hyperplasia. The aim of this study was to develop degradable sirolimus-eluting polymer coatings that can be applied on bioresorbable polymer-based scaffolds via an ultrasonic coating system. This is a novel approach because the detailed analysis of the coating procedure on bioresorbable polymeric scaffolds with the use of an ultrasonic system has not been reported thus far. It has been observed that the ultrasonic technique facilitates formation of a smooth coating, well-integrated with the scaffold. However, the drug dose is affected by the concentration of the coating solution and the number of layers. Therefore, these parameters can be used for tailoring the drug dose and release process. Although all types of the developed coatings provided sirolimus elution for at least 3 months, a more uniform, diffusion-controlled release profile was observed from coatings obtained from the 1.0% polymeric solution. The released drug showed antiproliferative activity against vascular SMCs, without any hemolytic or thrombogenic effects. The results of the study may be advantageous for further progress in the development and medical translation of polymeric vascular scaffolds with antirestenotic activity.
再狭窄是血管成形术期间支架植入后失败的主要原因。抗再狭窄药物的局部、持续递送可减少平滑肌细胞（SMC）增殖，从而限制新生内膜增生。本研究的目的是开发可降解的西罗莫司洗脱聚合物涂层，该涂层可通过超声涂层系统应用于基于生物可吸收聚合物的支架上。这是一种新颖的方法，因为迄今为止尚未报道使用超声系统对生物可吸收聚合物支架的涂层过程进行详细分析。据观察，超声技术有助于形成与支架良好整合的光滑涂层。然而，药物剂量受涂层溶液浓度和层数的影响。因此，这些参数可用于调整药物剂量和释放过程。尽管所有类型的开发涂层都能使西罗莫司洗脱至少3个月，但从1.0%聚合物溶液获得的涂层观察到更均匀、受扩散控制的释放曲线。释放的药物对血管SMC显示出抗增殖活性，没有任何溶血或血栓形成作用。该研究结果可能有利于具有抗再狭窄活性的聚合物血管支架的开发和医学转化取得进一步进展。
